This study has been transitioned to CTIS with ID 2024-510766-16-00 check the CTIS register for the current data. This trial evaluates the additional value of pre-emptive antibiotic treatment on clinically relevant OSIs in patients undergoing…
ID
Source
Brief title
Condition
- Malignant and unspecified neoplasms gastrointestinal NEC
- Hepatobiliary neoplasms malignant and unspecified
- Endocrine neoplasms malignant and unspecified
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary endpoint is the occurrence of a clinically relevant OSI and must
meet the following criteria (based on the CDC definition):
• A deep surgical site infection involving any part of the abdomen (e.g. organs
and/or spaces) other than the surgical incision within 90 days after surgery.
• AND Requires radiological, endoscopic or surgical intervention OR therapeutic
antibiotics required for an episode of sepsis, defined as two or more SIRS
criteria.
• AND Organisms isolated from an aseptically obtained culture.
Secondary outcome
The following secondary endpoints will be evaluated between patients receiving
perioperative prophylaxis versus pre-emptive antibiotic treatment (definitions
are outlined in Appendix A):
• OSI defined by the CDC definition within 90 days after surgery.
• Isolated OSI defined as an OSI without concurrent anastomotic leakage
(pancreatojejunostomy, hepaticojejunostomy or gastrojejunostomy). The concept
of an isolated OSI is used to separately classify abdominal infections without
concurrent anastomotic leakage.
• Superficial incisional SSI: defined according to the CDC definition: a
superficial surgical site infection occurring within 30 days after surgery
which involves superficial or deep soft tissue (skin, muscle or fascia, but no
intra-abdominal tissue), and at least one of the following criteria is present:
- Purulent drainage from the incision or subcutaneous tissue.
- Isolation of microorganisms from an aseptically obtained culture of fluid or
tissue from the superficial incision of subcutaneous tissue.
- Superficial infections of the skin or subcutaneous tissue which is
deliberately opened by a surgeon or attending physician OR at least one of the
following signs are present: localizes pain, tenderness, swelling, heat or
fever >38 degrees).
• Rate of clinically relevant postoperative pancreatic fistula (grade B or C
defined according to the ISGPS definition.
• Rate of bile and enteric leakage according to the ISGLS definition.
• Rate of postpancreatectomy hemorrhage according to the ISGPS definition.
• Rate of delayed gastric emptying according to the ISGPS definition.
• Rate of chyle leak according to the ISGPS definition.
• Rate of postoperative bacteraemia (defined as a positive blood culture)
• Rate of Clostridium difficile infection
• Rate of major complications, defined as a Clavien-Dindo score of >=III.
• Reintervention during admission (either radiological, surgical or endoscopic).
• ICU admission within 90 days after surgery.
• Length of hospital stay in days.
• Readmission within 90 days after surgery.
• In-hospital and 90-day mortality.
• Switch of postoperative antibiotics (including reason for deviation from
antibiotic protocol).
• Antibiotic sensitivity patterns in bile cultures and cultures from surgical
sites.
• Concordance of microorganisms in bile and surgical site cultures.
Background summary
The additional value of pre-emptive antibiotic treatment after
pancreatoduodenectomy is undetermined as previous research reported conflicting
results regarding infectious complications. Prolonged antibiotic prophylaxis
(formally pre-emptive antibiotic treatment) after pancreatoduodenectomy might
reduce the rate of surgical site infections in patients with a high risk for
contaminated bile (predominantly patients with preoperative biliary drainage or
an ampullary malignancy). Current national and international guidelines lack
clear recommendations regarding pre-emptive antibiotic treatment leading to
substantially varying antibiotic prophylactic regimes between institutes.
Study objective
This study has been transitioned to CTIS with ID 2024-510766-16-00 check the CTIS register for the current data.
This trial evaluates the additional value of pre-emptive antibiotic treatment
on clinically relevant OSIs in patients undergoing pancreatoduodenectomy with a
high risk for contaminated bile.
Study design
This multicenter, randomized controlled, superiority trial compares
perioperative versus pre-emptive antibiotic treatment during five postoperative
days after pancreatoduodenectomy in patients with a high risk for contaminated
bile.
Intervention
Participants will be randomized to either perioperative prophylaxis (cefazolin,
metronidazole and a single dose of 5-7mg/kg gentamicin, control arm) or
perioperative prophylaxis followed by cefuroxime and metronidazole for five
postoperative days (experimental arm).
Study burden and risks
Potential risks include inferiority of perioperative antibiotic prophylaxis
compared to five days of pre-emptive treatment with regard to the development
of infectious complications. However, current antibiotic prophylactic regimes
vary substantially between centers regarding type and duration. We hypothesize
that, in particular, patients with biliary drainage will benefit from
pre-emptive antibiotic treatment, which is currently suggested, but not
recommended by guidelines due to a lack of evidence. The results of this trial
will lead to recommendations for (inter)national guidelines about antibiotic
prophylactic regimes and a more appropriate and evidence-based use of
antibiotic prophylaxis for pancreatic surgery.
Albinusdreef 2
Leiden 2333ZA
NL
Albinusdreef 2
Leiden 2333ZA
NL
Listed location countries
Age
Inclusion criteria
• Patients undergoing elective pancreatoduodenectomy with a high risk for
contaminated bile defined as patients with preoperative biliary drainage or an
ampullary malignancy.
• Age of 18 years
Exclusion criteria
• Pregnancy
• Contraindication for the study antibiotics (e.g. allergy or intolerance)
• Indication for endocarditis prophylaxis
• Preoperative planned therapeutic antibiotic treatment after surgery (i.e. for
cholangitis or liver abscesses)
• A reduced renal function, defined as an eGFR of <60 ml/min/1.73m2 measured on
the closest timepoint prior to pancreatoduodenectomy
Design
Recruitment
Medical products/devices used
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
EU-CTR | CTIS2024-510766-16-00 |
EudraCT | EUCTR2022-003217-NL |
CCMO | NL82304.058.22 |